報價延遲最少15分鐘:2024/05/15 01:59 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.56 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.17/-1.51
|
|
企業價值
54.96M
|
| 資產負債 |
|
每股賬面淨值
-0.37
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
103.00K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/15 01:59 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patientswith solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. |